Fig. 1From: Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanomaTotal melanoma-specific costs (48 months) split across successive time intervals, per patient. NIVO + IPI nivolumab + ipilimumab cohort, NIVO nivolumab monotherapy cohort, IPI ipilimumab monotherapy cohortBack to article page